Delivery Order HHSN261201500018I-HHSN26100004
Award Date
6/15/17
Potential Completion Date
6/30/21
Potential Value
$979K
Federal Agency
National Cancer Institute
Ultimate Awardee
University Of Texas System
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Economy Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The University of Texas M.D. Anderson Cancer Center has been awarded a $854,290 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle held by the National Cancer Institute. Under this contract, M.D. Anderson will conduct optimization of dosing regimens of sulindac in combination with erlotinib for small intestinal and colon cancer prevention. The work directly supports the National Cancer Institute's PREVENT preclinical drug...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
The National Cancer Institute (NCI) awarded a $932,948 firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on "TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE." This delivery order falls under the NCI's PREVENT Preclinical Drug Development Program, which supports preclinical studies evaluating new treatments and biomarkers. MD Anderson, a component of the University of Texas...
This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a...
This is a firm fixed price delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $728,679.40, is for research to support the "Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)". The contract is part of the National Cancer Institute's...
This is a delivery order issued under the National Cancer Institute's Cancer Prevention Agent Development Program 2012-2017 indefinite delivery/indefinite quantity (IDIQ) contract. The contract was awarded to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to provide core infrastructure support for the program. The award has a ceiling value of $725,737.89 and an ultimate completion date of September 23, 2015. The contract is a cost-no-fee type...
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer...
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
This federal contract award is for the National Cancer Institute's Cancer Prevention Agent Development Program. The prime contractor is The University of Texas M.D. Anderson Cancer Center, a comprehensive cancer research and treatment center. The contract has a ceiling value of $4,248,160.62 and does not use a set-aside designation. The contract supports early phase clinical research, with the objective of developing cancer prevention agents. It includes subcontracts with several universities...